B lymphocytes in multiple sclerosis: Bregs and BTLA/CD272 expressing-CD19+ lymphocytes modulate disease severity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Piancone, Federica ^a   Saresella, Marina ^a   Marventano, Ivana ^a   La Rosa, Francesca ^a   Zoppis, Martina ^a   Agostini, Simone ^a   Longhi, Renato ^b   Caputo, Domenico ^a   Mendozzi, Laura ^a   Rovaris, Marco ^a   Clerici, Mario ^a,c  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BTLA PROTEIN, HUMAN; CD19 ANTIGEN; FINGOLIMOD; GAMMA INTERFERON; IMMUNOGLOBULIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ADULT; CELL CULTURE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; REGULATORY B LYMPHOCYTE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ANTIGENS, CD19; B-LYMPHOCYTES, REGULATORY; CELLS, CULTURED; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, IMMUNOLOGIC; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84978701110     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29699     Document Type: Article

References (62)

1. Villar, L. M. et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 115(1), 187-194 (2005).
2. Berger, T. et al. Antimyelin antibodies as a predictor of clinically defnite multiple sclerosis afer a frst demyelinating event. N. Engl. J. Med. 349(2), 139-145 (2003).
3. Genain, C. P. , Cannella, B., Hauser, S. L. & Raine, C. S. Identifcation of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5(2), 170-175 (1999).
4. Lund, F. E. Cytokine-producing B lymphocytes-key regulators of immunity. Curr. Opin. Immunol. 20(3), 332-338 (2008).
5. Fillatreau, S., Sweenie, C. H., McGeachy, M. J., Gray, D. & Anderton, S. M. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3, 944-950 (2002).
6. Mauri, C., Gray, D., Mushtaq, N. & Londei, M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 197(4), 489-501 (2003).
7. Mann, M. K., Maresz, K., Shriver, L. P. , Tan, Y. & Dittel, B. N. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J. Immunol. 178(6), 3447-3456 (2007).
8. Duddy, M. et al. Distinct efector cytokine profles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178(10), 6092-6099 (2007).
9. Saresella, M. et al. TH17-driven infammation is present in all clinical forms of multiple sclerosis; disease quiescence is associated with GATA3-expressing cells. Eur. J. Infamm. 11(1), 223-235 (2013).
10. Trabattoni, D. et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with diferent patterns of disease. J. Immunol. 183(8), 4984-4993 (2009).
11. Li, R. et al. Cytokine-Defned B Cell Responses as Terapeutic Targets in Multiple Sclerosis. Front. Immunol. 6, 626 (2016).
12. Ireland, S. J. et al. The efect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol. 71(11), 1421-1428 (2014).
13. Plant, S. R., Arnett, H. A. & Ting, J. P. Astroglial-derived lymphotoxin-alpha exacerbates infammation and demyelination, but not remyelination. Glia 49(1), 1-14 (2005).
14. Bar-Or, A. et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann. Neurol. 67(4), 452-461 (2010).
15. Saresella, M. et al. Toll-like receptor 3 diferently modulates infammation in progressive or benign multiple sclerosis. Clin. Immunol. 150(1), 109-120 (2014).
16. Bar-Or, A. et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 63, 395-400 (2008).
17. Barr, T. A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209(5), 1001-1010 (2012).
18. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4(7), 670-679 (2003).
19. Murphy, K. M., Nelson, C. A. & Sedí, J. R. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol. 6(9), 671-681 (2006).
20. M'Hidi, H. et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am. J. Clin. Pathol. 132(4), 589-596 (2009).
21. Nelson, C. A. et al. Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator. J. Immunol. 180(2), 940-947 (2008).
22. Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6(1), 90-98 (2005).
23. Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005).
24. Gonzalez, L. C. et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl. Acad. Sci. USA 102(4), 1116-1121 (2005).
25. Vendel, A. C. et al. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J. Immunol. 182(3), 1509-1517 (2009).
26. Kao, D., Lux, A., Schwab, I. & Nimmerjahn, F. Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Semin. Immunopathol. 36(3), 289-299 (2014).
27. Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
28. Kappos, L. et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378, 1779-1787 (2011).
29. Levesque, M. C. & St Clair, E. W. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J. Allergy Clin. Immunol. 121(1), 13-21 (2008).
30. Harris, D. P. , Goodrich, S., Gerth, A. J., Peng, S. L. & Lund, F. E. Regulation of IFN-gamma production by B efector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J. Immunol. 174(11), 6781-6790 (2005).
31. Harris, D. P., Goodrich, S., Mohrs, K., Mohrs, M. & Lund, F. E. Cutting edge: the development of IL-4-producing B cells (B efector 2 cells) is controlled by IL-4, IL-4 receptor alpha, and T2 cells. J. Immunol. 175(11), 7103-7107 (2005).
32. Fillatreau, S., Gray, D. & Anderton, S. M. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat. Rev. Immunol. 8(5), 391-397 (2008).
33. Rossi, S. et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler. 20(3), 304-312 (2014).
34. Centonze, D. et al. Infammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 29(11), 3442-3452 (2009).
35. Sun, L., He, C., Nair, L., Yeung, J. & Egwuagu, C. E. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine doi: 10.1016/j.cyto.2015.01.030 (2015).
36. Barr, T. A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6 producing B cells. J. Exp. Med. 209, 1001-1010 (2012).
37. Tedder, T. F. B10 cells: a functionally defned regulatory B cell subset. J. Immunol. 194(4), 1395-1401 (2015).
38. Matsushita, T. et al. Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response. Am. J. Pathol. 168, 812-821 (2006).
39. Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430 (2008).
40. Matsushita, T., Horikawa, M., Iwata, Y. & Tedder, T. F. Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J. Immunol. 185, 2240-2252 (2010).
41. Mizoguchi, A., Mizoguchi, E., Takedatsu, H., Blumberg, R. S. & Bhan, A. K. Chronic intestinal infammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16, 219-230 (2002).
42. Tian, J. et al. Lipopolysaccharide-activated B cells down-regulate T1 immunity and prevent autoimmune diabetes in non obese diabetic mice. J. Immunol. 167, 1081-1089 (2001).
43. Parekh, V. V. et al. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J. Immunol. 170, 5897-5911 (2003).
44. Rosser, E. C. & Mauri, C. Regulatory B cells: origin, phenotype, and function. Immunity, 42(4), 607-612 (2015).
45. Saresella, M., Rainone, V. , Al-Daghri, N. M., Clerici, M. & Trabattoni, D. The PD-1/PD-L1 pathway in human pathology. Curr. Mol. Med. 12(3), 259-267 (2012).
46. Shui, J. W., Steinberg, M. W. & Kronenberg, M. Regulation of infammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J. Leukoc. Biol. 89(4), 517-523 (2011).
47. Tibult, M. L. et al. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells. J. Mol. Med. (Berl). 91(2), 195-205 (2013).
48. Groves, A., Kihara, Y. & Chun, J. Fingolimod: direct CNS efects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J. Neurol. Sci. 328(1-2), 9-18 (2013).
49. Mehling, M. et al. Oral fngolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. Mult. Scler. J. 14, S234 (2008).
50. Claes, N. et al. Compositional changes of B and T cell subtypes during fngolimod treatment in multiple sclerosis patients: a 12-month follow-up study. PLoS One 9(10), e111115 (2014).
51. Miyazaki, Y. et al. Suppressed pro-infammatory properties of circulating B cells in patients with multiple sclerosis treated with fngolimod, based on altered proportions of B-cell subpopulations. Clin. Immunol. 151(2), 127-135 (2014).
52. Yuan, B. et al. A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis. Mol. Immunol. 57(2), 93-99 (2014).
53. Riou, C. et al. Diferential Impact of Magnitude, Polyfunctional Capacity, and Specifcity of HIV-Specifc CD8(+) T Cell Responses on HIV Set Point. J. Virol. 88, 1819-1824 (2014).
54. Rezai-Zadeh, K., Gate, D. & Town, T. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J. Neuroimmune. Pharmacol. 4(4), 462-475 (2009).
55. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature doi: 10.1038/nature14432 (2015).
56. Frischer, J. M. et al. The relation between infammation and neurodegeneration in multiple sclerosis brains. Brain 132, 1175-1189 (2009).
57. Krumbholz, M. et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is diferentially linked to CNS immune cell recruitment. Brain 129, 200-211 (2006).
58. Krumbholz, M. et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201, 195-200 (2005).
59. Corcione, A. et al. Recapitulation of B cell diferentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA 101, 11064-11069 (2004).
60. Obermeier, B. et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J. Neuroimmunol. 233, 245-248 (2011).
61. Uchiyama, M. et al. An agonistic anti-BTLA mAb (3C10) induced generation of IL-10- dependent regulatory CD4+ T cells and prolongation of murine cardiac allograf. Transplantation 97(3), 301-309 (2014).
62. Saresella, M. et al. Myelin basic protein-specifc T lymphocytes proliferation and programmed cell death in demyelinating diseases. Clin. Immunol. 129(3), 509-517 (2008).